GRAIL, Inc. (GRAL)
79.12
-3.42
(-4.14%)
USD |
NASDAQ |
Aug 26, 14:39
GRAIL Net Income (Quarterly) : -110.25M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -110.25M |
| March 31, 2026 | -93.19M |
| December 31, 2025 | -99.18M |
| September 30, 2025 | -88.98M |
| June 30, 2025 | -113.98M |
| March 31, 2025 | -106.21M |
| December 31, 2024 | -97.07M |
| September 30, 2024 | -125.69M |
| Date | Value |
|---|---|
| June 30, 2024 | -1.585B |
| March 31, 2024 | -218.91M |
| December 31, 2023 | -187.53M |
| September 30, 2023 | -891.45M |
| June 30, 2023 | -193.04M |
| March 31, 2023 | -193.67M |
| September 30, 2020 | -80.38M |
| September 30, 2019 | -60.68M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.536M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 44.69M |
| Total Expenses (Quarterly) | 154.93M |
| EPS Diluted (Quarterly) | -2.557 |
| Enterprise Value | 2.916B |
| Gross Profit Margin (Quarterly) | -30.61% |
| Profit Margin (Quarterly) | -246.7% |
| Earnings Yield | -12.32% |
| Normalized Earnings Yield | -11.80 |